Curtiss-Wright and Sintavia Deliver First Submarine Component Utilizing an Additively Manufactured Impeller to be Installed in a U.S. Navy Vessel
Curtiss-Wright’s EMS Division today announced that it has delivered the first submarine component with an additively manufactured (AM) impeller that will be installed in a U.S. Navy vessel.
Curtiss-Wright’s Engineered Pump Division (EPD) in Bethlehem, PA, Bechtel Plant Machinery Inc. (BPMI) in Monroeville, PA, and Sintavia, LLC in Fort Lauderdale, FL, collaborated to develop, manufacture, test, and supply the first submarine component utilizing a qualified, metal additively manufactured part. Sintavia, a leader in designing and manufacturing critical additively manufactured defense components, provided the AM impeller after a thorough qualification process. This impeller was assembled into the pump and tested at Curtiss-Wright’s facility in Bethlehem, PA.
Additive manufacturing technology offers a solution to the development of a product or component that historically has been difficult or costly to manufacture, often resulting in delays. The use of this technology is expected to provide a reliable and high-quality domestic source while also leading to shorter manufacturing lead times, increased quality, lower risk in performance, and improved delivery to further meet the needs of the U.S. Navy.
“Sintavia has proven to be an invaluable industry partner, and we are excited about the opportunity to further solidify our partnership by increasing the number of additively manufactured parts for this application and other critical naval defense components,” said David Micha, Sr. Vice President and General Manager of the EMS Division. “In addition, we are proud to be providing the first critical service equipment utilizing an additively manufactured component to the U.S. Navy’s submarine program and look forward to expanding these capabilities in the future to more efficiently serve our customer.”
“We would like to thank both Curtiss-Wright and BPMI for the opportunity to leverage Sintavia’s additive technology in the production of this critical component,” said Lindsay Lewis, Sintavia’s Corporate Vice President. “Leading-edge manufacturing processes such as AM will continue to be key differentiators in developing superior defense components in the years to come.”
Curtiss-Wright’s EPD business unit, part of Curtiss-Wright’s EMS division, and its predecessor companies have provided naval and maritime technological expertise and products since 1847. Today, EPD is a leading supplier of pumps and components that meet demanding and mission critical requirements for the world’s surface and submerged naval fleets. EPD also provides a wide range of spare and replacement parts, composite pump components, and support services for complete overhaul, upgrade, and in-field expertise. For more information, please visit www.cw-ems.com/epd.
About Curtiss-Wright Corporation
Curtiss-Wright Corporation is a global integrated business that provides highly engineered products, solutions and services mainly to Aerospace & Defense markets, as well as critical technologies in demanding Commercial Power, Process and Industrial markets. We leverage a workforce of approximately 8,600 highly skilled employees who develop, design and build what we believe are the best engineered solutions to the markets we serve. Building on the heritage of Glenn Curtiss and the Wright brothers, Curtiss-Wright has a long tradition of providing innovative solutions through trusted customer relationships. For more information, visit www.curtisswright.com.
About Sintavia
Sintavia is the world's first all-digital Aerospace & Defense component manufacturer. A founding member of the Additive Manufacturer Green Trade Association, Sintavia is committed to the highest quality standards in the industry and holds multiple Nadcap and other aerospace accreditations. For more information visit www.sintavia.com.
About Bechtel Plant Machinery, Inc.
Bechtel Plant Machinery, Inc. (BPMI) the U.S. Naval Nuclear Propulsion Program provides high quality nuclear power plant components for submarines and aircraft carriers. For more information, visit www.bpmionline.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203011953/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom